<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003056</url>
  </required_header>
  <id_info>
    <org_study_id>BAXTER-302302</org_study_id>
    <secondary_id>MCV-CCHR-9703-2A</secondary_id>
    <secondary_id>CDR0000065709</secondary_id>
    <secondary_id>NCI-G97-1311</secondary_id>
    <nct_id>NCT00003056</nct_id>
  </id_info>
  <brief_title>Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation</brief_title>
  <official_title>Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) for GVHD Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the&#xD;
      transplanted cells can make an immune response against the body's normal tissues.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of cyclosporine plus&#xD;
      methotrexate with cyclosporine plus T cell depletion for prevention of graft-versus-host&#xD;
      disease during peripheral stem cell transplantation in patients who have advanced leukemia or&#xD;
      lymphoma who are eligible for transplanted peripheral stem cells from a donor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Demonstrate that the graft versus host disease (GVHD) prophylactic regimen&#xD;
      consisting of T-cell depletion and cyclosporine results in less toxicity than the control&#xD;
      regimen of methotrexate and cyclosporine in recipients of peripheral blood stem cell&#xD;
      transplants. II. Monitor safety of the two regimens in order to assure that the treatment&#xD;
      regimen dose not result in any increase in serious or unexpected toxicities, does not&#xD;
      compromise the efficacy of GVHD prophylaxis, and does not compromise the efficacy of the&#xD;
      disease therapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter, controlled, randomized trial. Patients are assigned to high&#xD;
      or low risk groups and randomized to the control or treatment arms. Patients are stratified&#xD;
      by risk group and by site. Mobilization, apheresis, and successful cryopreservation of the&#xD;
      minimum number of CD34 cells for transplant has to be achieved prior to initiating&#xD;
      cytoreductive therapy. Following intensive cytoreductive therapy, patients receive either&#xD;
      unselected peripheral blood stem cells (PBSC) together with the control graft versus host&#xD;
      disease (GVHD) prophylaxis regimen or CD34+ cells isolated from PBSC with cyclosporine. In&#xD;
      the control group, GVHD prophylaxis consists of two drug therapies, cyclosporine and&#xD;
      methotrexate. The cyclosporine is administered first by IV continuous infusion and then later&#xD;
      orally, twice a day, in decreasing increments for 180 days. Methotrexate is administered by&#xD;
      IV on days 1, 3, 6, and 11. Cyclosporine is discontinued after day +180 if there is no&#xD;
      evidence of GVHD. In the treatment group, GVHD prophylaxis consists of T cell depletion of&#xD;
      the transplant product using the Isolex positive selection procedure (Isolex selected CD34+&#xD;
      cells) and cyclosporine. The cyclosporine is administered at the same doses and increments as&#xD;
      in the control group. In cases where there still is acute or chronic GVHD, the patient is&#xD;
      given the appropriate salvage regimens. Patients are followed monthly for 6 months after&#xD;
      transplant, and then for 2 years to monitor relapses.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 200 patients accrued (100 in each arm) in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis indicated study should be terminated&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 1997</start_date>
  <completion_date type="Actual">June 1, 2003</completion_date>
  <primary_completion_date type="Actual">June 1, 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Month 1, post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Month 2, post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Month 3, post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Month 4, post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Month 5, post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Month 6, post-transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Unselected peripheral blood haemopoietic stem cells (PBSC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD34+ cells isolated from PBSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>CD34+ cells isolated from PBSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine and methotrexate</intervention_name>
    <arm_group_label>Unselected peripheral blood haemopoietic stem cells (PBSC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: - Acute lymphocytic leukemia (ALL) with documented&#xD;
        chemosensitivity (complete response [CR], partial response [PR], or minor response [MR]) in&#xD;
        first or second remission, first or second relapse, or high risk ALL with Ph positive 9/22&#xD;
        translocation; OR - Acute myelogenous leukemia (AML) with documented chemosensitivity (CR,&#xD;
        PR, or MR) in first or second remission, or first or second relapse; OR - Chronic&#xD;
        myelogenous leukemia (CML), chronic or accelerated, that is not in blast crisis; OR -&#xD;
        Hodgkin's disease or non-Hodgkin's lymphoma with documented chemosensitivity in first or&#xD;
        second relapse Consenting human lymphocyte antigen (HLA)-identical related donor required&#xD;
        No active central nervous system (CNS) or skin leukemia involvement No disease that&#xD;
        requires additional mediastinal radiation&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18-55 Performance status: Karnofsky 70-100% Life expectancy:&#xD;
        Greater than 8 weeks Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5 times&#xD;
        normal serum glutamate oxalo-acetate transaminase (SGOT) less than 2 times normal Renal:&#xD;
        Creatinine less than 1.5 times normal Cardiovascular: Left ventricular ejection fraction at&#xD;
        rest at least 40% or within normal range Pulmonary: diffusing capacity of the lung for&#xD;
        carbon monoxide (DLCO) greater than 45% of predicted or within normal range Other: HIV&#xD;
        negative At least 2 weeks since any active infection requiring intravenous treatment with&#xD;
        antifungal, antibacterial or antiviral agents with the exception of coagulase negative&#xD;
        staphylococcal line infection No coexisting medical problems that would significantly&#xD;
        increase the risk of the transplant procedure Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: No more that 2 prior therapy regimens Biologic therapy: No prior&#xD;
        autologous or allogeneic bone marrow or peripheral blood stem cell transplant Chemotherapy:&#xD;
        Not specified Endocrine therapy: Not specified Radiotherapy: Prior radiation therapy&#xD;
        subject to dose requirements Surgery: Not specified Other: At least 2 weeks since&#xD;
        intravenous treatment with antifungal, antibacterial or antiviral agents, except for&#xD;
        treatment of coagulase negative staphylococcal infection of an IV or central line&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2004</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

